US Congress House Bill 2113 (Prior Session Legislation)

---

Spectrum: Slight Partisan Bill (Democrat 9-3)
Status: Introduced on April 8 2019 - 25% progression, died in chamber
Action: 2020-12-24 - Placed on the Union Calendar, Calendar No. 571.
Text: Latest bill text (Introduced) [PDF]

Establishes requirements for prescription drug manufacturers to provide certain information about pricing, discounts, and product samples of applicable drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to annually determine whether there are price increases of a certain threshold for outpatient prescription drugs covered under Medicare, excluding low-cost drugs.Manufacturers must provide HHS with an explanation for drug prices that (1) cumulatively increase by at least 10% or $10,000 over one year; (2) cumulatively increase by at least 25% or $25,000 over three years; or (3) are at least $26,000 annually, per individual, if first covered by Medicare during the applicable year. The manufacturer must explain the role of the factors contributing to such prices and other relevant information, including manufacturing costs, marketing costs, and revenue. Additionally, drug manufacturers must provide HHS with aggregate data related to product samples of drugs, devices, biologic products, and medical supplies given to hospitals, physicians, or other medical professionals during the previous calendar year, beginning in 2023.The bill further requires HHS to make publicly available the information related to drug discounts, rebates, and price concessions that is provided annually to HHS by group health plans. Drug manufacturers also must report to HHS certain sales information for drugs available under Medicare for which the manufacturer does not have a rebate agreement in place.The bill requires HHS to study and report on trends concerning inpatient hospital drug costs.

Prescription Drug STAR Act Prescription Drug Sunshine, Transparency, Accountability and Reporting Act

Rep. Richard Neal [D-MA]	Rep. Kevin Brady [R-TX]	Rep. Jeff Van Drew [R-NJ]	Rep. Abby Finkenauer [D-IA]
Rep. Chrissy Houlahan [D-PA]	Rep. Jamie Raskin [D-MD]	Rep. Ben McAdams [D-UT]	Rep. Lauren Underwood [D-IL]
Rep. Elissa Slotkin [D-MI]	Rep. Daniel Lipinski [D-IL]	Rep. Zoe Lofgren [D-CA]	Rep. Mark Amodei [R-NV]

Date	Chamber	Action
2020-12-24	House	Placed on the Union Calendar, Calendar No. 571.
2020-12-24	House	Committee on Energy and Commerce discharged.
2020-12-24	House	Reported (Amended) by the Committee on Ways and Means. H. Rept. 116-688, Part I.
2019-04-09	House	Referred to the Subcommittee on Health.
2019-04-09	House	Ordered to be Reported by Voice Vote.
2019-04-09	House	Committee Consideration and Mark-up Session Held.
2019-04-08	House	Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-04-08	House	Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-04-08	House	Referred to the Subcommittee on Health.
2019-04-08	House	Introduced in House

HB2087 (Related) 2019-05-21 - Subcommittee Hearings Held.
HB2069 (Related) 2019-05-21 - Subcommittee Hearings Held.
HB2115 (Related) 2019-10-29 - Received in the Senate and Read twice and referred to the Committee on Finance.
SB2051 (Related) 2019-06-28 - Read twice and referred to the Committee on Finance.
HB2064 (Related) 2019-05-21 - Subcommittee Hearings Held.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/house-bill/2113/all-info
Text	https://www.congress.gov/116/bills/hr2113/BILLS-116hr2113ih.pdf
Text	https://www.congress.gov/116/bills/hr2113/BILLS-116hr2113rh.pdf